AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) An isolated nucleic acid molecule according to any one of SEQ ID NO:s 2, 4, 7, 9, 12, 14, 17, 19, 21, 24, 26, 29, 31, 34, 36, 39, 41, 44, 46, 49, ~~and 51 or~~ or 51, a fragment or analogue thereof, or an isolated nucleic acid molecule which hybridizes to one of the foregoing sequences under stringent conditions and which has the ability to stimulate or inhibit one or more of ~~at least one biological activity selected from the group consisting of~~ vasculogenesis, angiogenesis, vascular permeability, endothelial cell proliferation, endothelial cell differentiation, endothelial cell migration, [and] or endothelial cell survival~~, or an isolated nucleic acid molecule which hybridizes to one of the foregoing sequences under stringent conditions~~.

2. (Currently Amended) An isolated nucleic acid molecule which hybridizes to ~~the~~ a compliment of a nucleic acid molecule according to ~~Claim 1~~ claim 1 under stringent conditions.

3. (Currently Amended) An isolated siRNA molecule targeted to an isolated nucleic acid molecule according to ~~Claims 1 or 2~~ claim 1, wherein the isolated siRNA molecule is at least 19 base pairs long.

4. (Currently Amended) An expression vector comprising the isolated nucleic acid according to ~~Claims 1 or 2~~ claim 2, ~~optionally~~ wherein the nucleic acid may be operatively associated with a regulatory nucleic acid controlling the expression of the polypeptide encoded by ~~said~~ the nucleic acid.

5. (Currently Amended) A host cell genetically engineered to contain [a] the isolated nucleic acid according to ~~Claims 1 or 2~~ claim 1.

6. (Currently Amended) A host cell transfected with an expression vector according to ~~Claim 4~~ claim 4.

7. (Currently Amended) A method of treating an angiogenesis-related condition in a cell, group of cells, or organism, comprising the step of administering an expression vector according to ~~Claim 4~~ claim 4 to the cell, group of cells, or organism.

8. (Currently Amended) An antibody with specific reactivity to a nucleic acid according to ~~Claims 1 or 2~~ claim 1, wherein the antibody may preferably be polyclonal or monoclonal and wherein the antibody may further comprise a detectable label such as a fluorescent label.

9. (Currently Amended) A transgenic, non-human animal which has been

genetically engineered to contain a transgene comprising a nucleic acid according to ~~Claims 1 or 2, preferably,~~ claim 1, so that the transgene may be expressed.

10. (Currently Amended) A pharmaceutical composition comprising [a] an isolated nucleic acid sequence according to ~~Claims 1 or 2~~ claim 1.

11. (Currently Amended) A method of affecting vasculogenesis or angiogenesis in a cell, group of cells, or organism, comprising ~~the step of~~ administering a pharmaceutical composition according to ~~Claim 16~~ claim 16 to the cell, group of cells, or organism, wherein the pharmaceutical composition causes ~~the affecting may preferably cause~~ an increase or decrease~~, more preferably,~~ in the cell, group of cells, or organism, and wherein the organism has an angiogenesis-related disorder such as cancer, retinopathy, macular degeneration, corneal ulceration, stroke, ischemic heart disease, infertility, ulcers, ~~scleradoma~~ scleroderma, wound healing, ischemia, ischemic heart disease, myocardial infarction, myocardosis, angina pectoris, unstable angina, coronary arteriosclerosis, arteriosclerosis obliterans, Berger's disease, arterial embolism, arterial thrombosis, cerebrovascular occlusion, cerebral infarction, cerebral thrombosis, cerebral embolism, rubeosis proliferative vitreoretinopathy, chronic inflammation, inflammatory bowel disease, psoriasis, sarcoidosis [and] or rheumatoid arthritis.

12. (Currently Amended) An isolated polypeptide comprising a sequence of

amino acids substantially corresponding to [the] an amino acid sequence in any one of SEQ ID NO:s 3, 5, 8, 10, 13, 15, 18, 20, 22, 25, 27, 30, 32, 35, 37, 40, 42, 45, 47, 50, and 52, or a fragment or analogue thereof, ~~said~~ the isolated polypeptide having the ability to affect angiogenesis in a cell, a group of cells, or an organism.

13. (Currently Amended) A host cell genetically engineered to express [a] an isolated polypeptide according to ~~Claim 12~~ claim 12.

14. (Currently Amended) An antibody specifically reactive with a polypeptide according to ~~Claim 12~~ claim 12, wherein the antibody may ~~preferably~~ be polyclonal or monoclonal, and wherein the antibody may further comprise a detectable label such as a fluorescent label.

15. (Currently Amended) A transgenic, non-human animal which has been genetically engineered to contain a transgene comprising a nucleic acid which encodes [a] an isolated polypeptide according to ~~Claim 12, preferably,~~ claim 12 so that the transgene may be expressed.

16. (Currently Amended) A pharmaceutical composition comprising an isolated polypeptide according to ~~Claim 12~~ claim 12.

17. (Currently Amended) A method of ~~affecting~~ causing vasculogenesis or

angiogenesis in a cell, group of cells, or organism, comprising the step of administering a pharmaceutical composition according to ~~Claim 16~~ claim 16 to the cell, group of cells, or organism, the affecting may preferably cause an increase or decrease, more preferably, the cell, group of cells, or organism that has an angiogenesis-related disorder such as cancer, retinopathy, macular degeneration, corneal ulceration, stroke, ischemic heart disease, infertility, ulcers, ~~scleradoma~~ scleroderma, wound healing, ischemia, ischemic heart disease, myocardial infarction, myocardosis, angina pectoris, unstable angina, coronary arteriosclerosis, arteriosclerosis obliterans, Berger's disease, arterial embolism, arterial thrombosis, cerebrovascular occlusion, cerebral infarction, cerebral thrombosis, cerebral embolism, rubeosis proliferative vitreoretinopathy, chronic inflammation, inflammatory bowel disease, psoriasis, sarcoidosis, or ~~and~~ rheumatoid arthritis.

18. (Currently Amended) A method of detecting an angiogenesis-related transcript in a cell of a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence according to any one of SEQ ID NO:s 2, 4, 7, 9, 12, 14, 17, 19, 21, 24, 26, 29, 31, 34, 36, 39, 41, 44, 46, 49, and 51, wherein an angiogenesis-related transcript is detected where hybridization is detected, ~~preferably~~ wherein the polynucleotide comprises a sequence according to any one of SEQ ID NO:s 2, 4, 7, 9, 12, 14, 17, 19, 21, 24, 26, 29, 31, 34, 36, 39, 41, 44, 46, 49, and 51, ~~preferably~~ wherein the biological sample is a tissue sample or is

comprised of isolated nucleic acids such as mRNA, ~~preferably~~ wherein the nucleic acids are amplified prior to ~~the step of~~ contacting the biological sample with the polynucleotide, ~~preferably~~ and wherein the polynucleotide is immobilized on a solid surface.

19. (Currently Amended) A method of affecting ~~at least one bioactivity selected from~~ angiogenesis and/or vasculogenesis in a vertebrate organism, ~~said~~ the method comprising ~~the step of~~ administering to ~~said~~ the organism an effective angiogenesis [or] and/or vasculogenesis affecting amount of a nucleotide ~~or polypeptide~~ according to ~~Claims 1 or 12~~ claim 1, wherein the organism is preferably a mammal such as mice, rats, rabbits, guinea pigs, cats, dogs, pigs, cows, monkeys, and humans, wherein vasculogenesis or angiogenesis is ~~preferably~~ enhanced, increased, inhibited, or decreased, and wherein the organism preferably has an angiogenesis-related disorder such as cancer, retinopathy, macular degeneration, corneal ulceration, stroke, ischemic heart disease, infertility, ulcers, ~~scleradoma~~ scleroderma, wound healing, ischemia, ischemic heart disease, myocardial infarction, myocardosis, angina pectoris, unstable angina, coronary arteriosclerosis, arteriosclerosis obliterans, Berger's disease, arterial embolism, arterial thrombosis, cerebrovascular occlusion, cerebral infarction, cerebral thrombosis, cerebral embolism, rubeosis proliferative vitreoretinopathy, chronic inflammation, inflammatory bowel disease, psoriasis, sarcoidosis, or ~~and~~ rheumatoid arthritis.

20. (Original) A transgenic increased or decreased angiogenesis laboratory animal comprising one or more cells in which the expression of a sequence according to any one of SEQ ID NO:s 2, 4, 7, 9, 12, 14, 17, 19, 21, 24, 26, 29, 31, 34, 36, 39, 41, 44, 46, 49, and 51 is upregulated, downregulated, or absent.

21. (New) A method of affecting angiogenesis and/or vasculogenesis in a vertebrate organism, the method comprising administering to the organism an effective angiogenesis and/or vasculogenesis affecting amount of a polypeptide according to claim 12, wherein the organism is preferably a mammal such as mice, rats, rabbits, guinea pigs, cats, dogs, pigs, cows, monkeys, and humans, wherein vasculogenesis or angiogenesis is enhanced, increased, inhibited, or decreased, and wherein the organism preferably has an angiogenesis-related disorder such as cancer, retinopathy, macular degeneration, corneal ulceration, stroke, ischemic heart disease, infertility, ulcers, scleroderma, wound healing, ischemia, ischemic heart disease, myocardial infarction, myocardosis, angina pectoris, unstable angina, coronary arteriosclerosis, arteriosclerosis obliterans, Berger's disease, arterial embolism, arterial thrombosis, cerebrovascular occlusion, cerebral infarction, cerebral thrombosis, cerebral embolism, rubeosis proliferative vitreoretinopathy, chronic inflammation, inflammatory bowel disease, psoriasis, sarcoidosis, or rheumatoid arthritis.